In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti-TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.

An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Interleukin-18-binding protein as diagnostic and prognostic biomarker assays in renal injuries.

Some embodiments are directed to a method for the in vitro detection/prediction of imminent childbirth based on the detection of at least two of the following markers: insulin-like growth factor-binding protein 1 (IGFBP-1), a N-terminal fragment of insulin-like growth factor-binding protein 1, and interleukin 6 (IL-6). Some embodiments are also directed to a device for the implementations of the method. Some embodiments are applicable in the medical field, in the diagnostic field, and in particular in the obstetric field.

The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

De novo designed polypeptides that bind to IL-2 receptor βγ.sub.c heterodimer (IL-2Rβγ.sub.c), IL-4 receptor αγ.sub.cheterodimer (IL-4Rαγ.sub.c), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.

The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.

Provided are methods and systems for determining functional relationships between ex vivo skin models and an inflammatory skin condition. Also provided are methods and systems for identifying modulators of inflammation of skin, as well as the use of modulators identified by such methods or systems for the preparation of cosmetic compositions, personal care products, or both.

The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.

Described herein are methods and kits for performing plasmon-enhanced fluoro-dot assays. These assays enable observing a correlation between a chemical stimulus and a biological response of cultured cells in vitro.